Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype

Llanos, Adana A. M.; Lin, Yong; Chen, Wenjin; Yao, Song; Norin, Jorden; Chekmareva, Marina A.; Omene, Coral; Cong, Lei; Omilian, Angela R.; Khoury, Thaer; Hong, Chi-Chen; Ganesan, Shridar; Foran, David J.; Higgins, Michael; Ambrosone, Christine B.; Bandera, Elisa V.; Demissie, Kitaw

doi:10.1186/s13058-020-1256-3

Table 3 Multivariate mixed effects models of the associations of adipokine and adipokine receptor IHC expression with breast tumor clinicopathologic features in the overall study sample

From: Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype

Breast tumor clinicopathologic features	LEP		LEPR		ADIPOQ		ADIPOR1		ADIPOR2
Breast tumor clinicopathologic features	Diff of LS means (SE)	P	Diff of LS means (SE)	P	Diff of LS means (SE)	P	Diff of LS means (SE)	P	Diff of LS means (SE)	P
Tumor grade
Moderately vs. well differentiated	2.44 (3.29)	0.46	− 1.25 (3.25)	0.70	− 2.61 (4.31)	0.54	− 0.49 (4.26))	0.91	− 2.63 (4.19)	0.53
Poorly vs. well differentiated	2.88 (3.16)	0.36	− 5.52 (3.12)	0.08	− 1.97 (4.17)	0.64	1.92 (4.11)	0.64	2.58 (4.05)	0.53
Tumor size
1.0–2.0 cm vs. < 1.0 cm	0.70 (2.84)	0.80	6.25 (2.81)	0.03	− 9.72 (3.60)	0.007	− 6.50 (3.72)	0.08	− 5.62 (3.57)	0.12
> 2.0 cm vs. < 1.0 cm	− 1.12 (2.83)	0.69	3.32 (2.79)	0.24	− 7.86 (3.60)	0.03	− 6.49 (3.71)	0.08	4.11 (3.56)	0.25
AJCC stage
Stage I vs. stage 0	2.80 (4.11)	0.50	− 3.02 (3.99)	0.45	− 2.95 (5.03)	0.56	8.95 (5.18)	0.08	− 4.61 (5.03)	0.36
Stage II vs. stage 0	2.02 (4.08)	0.62	− 1.39 (3.96)	0.73	− 4.97 (4.99)	0.32	2.06 (5.13)	0.69	− 1.40 (4.99)	0.78
Stage III/IV vs. stage 0	− 2.90 (4.60)	0.53	− 5.93 (4.50)	0.19	− 9.02 (5.71)	0.11	2.30 (5.87)	0.69	1.26 (5.71)	0.83
Lymph node status
Positive vs. negative	1.21 (2.20)	0.58	1.13 (2.16)	0.60	0.63 (2.83)	0.83	0.10 (2.89)	0.97	4.65 (2.78)	0.09
Ki67 status
Ki67+/unfavorable vs. Ki67−/favorable	3.25 (2.29)	0.16	− 4.00 (2.35)	0.09	− 7.16 (3.28)	0.03	− 3.96 (3.47)	0.26	0.81 (3.30)	0.81
ER status
ER− vs. ER+	− 1.17 (2.20)	0.59	− 10.47 (2.20)	< 0.0001	0.14 (2.91)	0.96	1.91 (3.00)	0.52	2.97 (2.89)	0.31
PR status
PR− vs. PR+	− 1.92 (2.03)	0.34	− 9.54 (2.02)	< 0.0001	− 1.59 (2.67)	0.55	− 1.14 (2.75)	0.68	4.98 (2.65)	0.06
HER2 status
HER2+ vs. HER2−	3.57 (2.55)	0.16	− 1.42 (2.60)	0.58	2.79 (3.43)	0.42	2.70 (3.50)	0.44	2.08 (3.41)	0.54
Breast cancer subtype^a
Luminal B vs. luminal A	7.22 (3.65)	0.05	1.64 (3.66)	0.65	4.65 (4.89)	0.34	3.41 (4.48)	0.49	− 0.61 (4.83)	0.90
HER2-E vs. luminal A	0.59 (3.37)	0.86	− 9.46 (3.37)	0.005	1.21 (4.56)	0.79	3.90 (4.65)	0.40	7.09 (4.52)	0.12
TN vs. luminal A	0.13 (2.50)	0.96	− 10.92 (2.57)	< 0.0001	0.04 (3.39)	0.99	3.54 (3.46)	0.31	5.24 (3.36)	0.12

Differences of least squares means were generated using multivariate mixed effects models controlling for race, BMI, and menopausal status. Each model also mutually controlled for the other four biomarkers examined
^aBreast cancer subtypes were classified based on IHC expression of ER and PR, and overexpression or amplification of HER2 (by IHC or FISH) as reported in pathology records

Back to article page